<?xml version="1.0" encoding="UTF-8"?>
<urlset xmlns="http://www.sitemaps.org/schemas/sitemap/0.9" xmlns:news="http://www.google.com/schemas/sitemap-news/0.9">
  <url><loc>https://psiconautica.org/noticias/nexus-2026-consciencia-arte-libertad/</loc><news:news><news:publication><news:name>Psiconáutica</news:name><news:language>es</news:language></news:publication><news:publication_date>2026-07-21T12:48:01+02:00</news:publication_date><news:title>Nexus 2026: consciencia, arte y libertad en los márgenes</news:title></news:news></url>
  <url><loc>https://psiconautica.org/noticias/psilocibina-migrana-ensayo-piloto-yale-2026/</loc><news:news><news:publication><news:name>Psiconáutica</news:name><news:language>es</news:language></news:publication><news:publication_date>2026-07-21T11:49:11+02:00</news:publication_date><news:title>Psilocibina para la migraña: respuesta del 80% en un ensayo piloto de Yale</news:title></news:news></url>
  <url><loc>https://psiconautica.org/noticias/ketamina-receptores-ampa-depresion-resistente-estudio-pet/</loc><news:news><news:publication><news:name>Psiconáutica</news:name><news:language>es</news:language></news:publication><news:publication_date>2026-07-21T11:09:11+02:00</news:publication_date><news:title>La ketamina repara circuitos cerebrales en la depresión resistente</news:title></news:news></url>
  <url><loc>https://psiconautica.org/noticias/eli-lilly-compra-ataibeckley-5-meo-dmt-depresion-resistente/</loc><news:news><news:publication><news:name>Psiconáutica</news:name><news:language>es</news:language></news:publication><news:publication_date>2026-07-21T10:29:12+02:00</news:publication_date><news:title>Eli Lilly compra por 3.800 millones el spray nasal de 5-MeO-DMT</news:title></news:news></url>
  <url><loc>https://psiconautica.org/noticias/oregon-duplicar-tasas-programa-psilocibina/</loc><news:news><news:publication><news:name>Psiconáutica</news:name><news:language>es</news:language></news:publication><news:publication_date>2026-07-21T09:49:13+02:00</news:publication_date><news:title>Oregón plantea duplicar las tasas de su programa legal de psilocibina</news:title></news:news></url>
  <url><loc>https://psiconautica.org/noticias/psilocibina-anorexia-nerviosa-ensayo-piloto-imperial-college/</loc><news:news><news:publication><news:name>Psiconáutica</news:name><news:language>es</news:language></news:publication><news:publication_date>2026-07-20T11:14:49+02:00</news:publication_date><news:title>Psilocibina en anorexia nerviosa: un ensayo piloto muestra mejoras sostenidas al año</news:title></news:news></url>
  <url><loc>https://psiconautica.org/noticias/ketamina-oral-liberacion-prolongada-menos-disociacion-esketamina/</loc><news:news><news:publication><news:name>Psiconáutica</news:name><news:language>es</news:language></news:publication><news:publication_date>2026-07-20T10:34:50+02:00</news:publication_date><news:title>Ketamina oral de liberación prolongada: menos disociación en un ensayo con esketamina</news:title></news:news></url>
  <url><loc>https://psiconautica.org/noticias/dmt-ayahuasca-parkinson-receptor-sigma-1-ucm/</loc><news:news><news:publication><news:name>Psiconáutica</news:name><news:language>es</news:language></news:publication><news:publication_date>2026-07-20T09:54:51+02:00</news:publication_date><news:title>La DMT de la ayahuasca protege neuronas en un modelo animal de párkinson</news:title></news:news></url>
  <url><loc>https://psiconautica.org/noticias/lsd-aprendizaje-motor-plasticidad-cerebral-estudio-suiza/</loc><news:news><news:publication><news:name>Psiconáutica</news:name><news:language>es</news:language></news:publication><news:publication_date>2026-07-20T09:14:51+02:00</news:publication_date><news:title>Una dosis de LSD mejora el aprendizaje motor al día siguiente, según un estudio suizo</news:title></news:news></url>
  <url><loc>https://psiconautica.org/noticias/comp360-psilocibina-supera-ensayo-fase-3/</loc><news:news><news:publication><news:name>Psiconáutica</news:name><news:language>es</news:language></news:publication><news:publication_date>2026-07-19T18:13:21+02:00</news:publication_date><news:title>COMP360: la psilocibina farmaceutica supera su ensayo clave de fase 3</news:title></news:news></url>
  <url><loc>https://psiconautica.org/noticias/lsd-farmaceutico-fase-3-depresion-mayor-emerge/</loc><news:news><news:publication><news:name>Psiconáutica</news:name><news:language>es</news:language></news:publication><news:publication_date>2026-07-19T17:33:22+02:00</news:publication_date><news:title>Una dosis única de LSD farmacéutico reduce la depresión mayor en fase 3</news:title></news:news></url>
  <url><loc>https://psiconautica.org/noticias/buprenorfina-prolonga-efecto-antisuicida-ketamina/</loc><news:news><news:publication><news:name>Psiconáutica</news:name><news:language>es</news:language></news:publication><news:publication_date>2026-07-19T16:53:22+02:00</news:publication_date><news:title>Buprenorfina a dosis bajas prolonga un mes el efecto antisuicida de la ketamina</news:title></news:news></url>
</urlset>